Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat

Inclusion Criteria: * Patients with stable CAD (coronary artery disease) defined by: * clinically stable for at least 3 months * coronary artery stenosis in any of the 3 main coronary vessels * or history of myocardial infarction * Sinus rhythm at screening * Interpretable echocardiographic images * Age: 30 to 80 years * Body mass index (BMI): above/equal 18.0 and below/equal 36.0 kg/m² Exclusion Criteria: * Ejection fraction (EF) below 30% at screening * Progressive angina with symptoms of worsening of angina within the \<3 month * History of recent myocardial infarction or unstable Angina * Documented current relevant coronary stenosis ≥90% in any of the main 3 coronary vessels without bypass graft * Symptomatic carotid stenosis, or transient ischemic attack or stroke within 3 months or patients with stroke at more than 3 months * Insulin dependent diabetes mellitus * Clinically significant and persisting cardiac ischemia * Atrial fibrillation, pacemaker, defibrillator, second and third degree atrial-ventricular (AV) block * Known clinically relevant ventricular arrhythmias * Clinically relevant heart failure with reduced left ventricular ejection fraction * Significant valvular heart disease with moderate or severe aortic stenosis or any other significant stenosis; any other moderate or severe valvular failures * Valve replacement * Hypertrophic obstructive cardiomyopathy (HOCM) * Previous or imminent cardiac transplantation * Known long QT syndrome or prolongation of the QT interval with ongoing proarrhythmic conditions * Co-medication with drugs known to have QT prolonging effect * Intolerance of fluoroquinolones, including moxifloxacin * History of serious adverse effects e.g. tendinitis and tendon rupture, arthralgia and effects on the peripheral and central nervous system while taking fluoroquinolones including moxifloxacin * History of tendon diseases or tendon injury caused by quinolones * Treatment with fluoroquinolones, including moxifloxacin during the last 2 weeks * Treatment with organic nitrates during the last 3 months * Treatment with riociguat during the last 3 months * Treatment with phosphodiesterase (PDE)-5 inhibitors during the last 14 days * Systolic blood pressure below 110 or above 160 mmHg at screening visit * Diastolic blood pressure below 50 or above 100 mmHg at screening visit * Heart rate below 50 or above 100 beats/min (taken from ECG measurement) at first screening visit * Estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73m\*2